GET DAILY SIGNALSOdyssey Therapeutics (ODTX): Analysts See +82% Upside to $35 Target
Key Takeaways
- The central target of $35 is the arithmetic mean of six current, individually attributed analyst price targets, rounded from roughly $34.67, and implies about 82% upside from the latest price near $19.23.
- Individual verified targets range from a low of $27 (UBS) to a high of $42 (Raymond James), with all six covering firms rating the stock Buy/Outperform/Overweight.
- Odyssey Therapeutics, Inc. (ODTX) is a Boston-based clinical-stage biopharmaceutical company developing precision immunomodulators for autoimmune and inflammatory diseases, led by oral RIPK2 inhibitor OD-001 in ulcerative colitis.
- The strongest supporting factor is a broadly positive analyst setup tied to OD-001's Phase 2a proof-of-concept data and planned later-stage trials, rather than current revenue or earnings.
- The biggest risks are execution and binary clinical outcomes, a pre-revenue model with ongoing net losses, and the fact that the target sits well above the stock's 52-week high of $29.05.
- For more context on the company, you can explore the Major News, Today's Price Move, Forecast, and Earnings pages.
- Investors seeking a systematic view of changing conditions may also want to explore Trending AI Robots for automated signal ideas.
Analyst Price Targets and Consensus View
Odyssey Therapeutics is a stock with meaningful, current analyst coverage. Reviewing the most recent individually attributed targets from each covering firm yields six distinct price objectives: $27 (UBS, initiated Buy in October 2026), $29 (J.P. Morgan, Overweight, raised from $26 in August 2026), $30 (Wedbush, Outperform), $40 (Oppenheimer, Outperform), $40 (H.C. Wainwright, Buy), and $42 (Raymond James, initiated Outperform in October 2026).
The arithmetic mean of these six targets is about $34.67, which rounds to the $35 central target used here. The range is wide — roughly $27 to $42 — reflecting genuine disagreement about how much the pipeline is worth. All six firms rate the shares positively, but there is no "hold" or "sell" view among those publishing targets, which is itself a notable skew.
Analyst reasoning centers overwhelmingly on ODTX's lead candidate OD-001, an oral RIPK2 scaffolding inhibitor that has shown proof-of-concept results in ulcerative colitis, with the ulcerative colitis market often cited as a roughly $10 billion opportunity. H.C. Wainwright previously carried a $44 target before most recently setting $40, while J.P. Morgan's earlier $26 target was lifted to $29 — a sign of modestly shifting assumptions rather than a unanimous, stable consensus. These are individual research opinions, not a guarantee of future performance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
At its latest verified close near $19.23, Odyssey Therapeutics would need to rise roughly 82% to reach $35 — a very large move by any standard. The company listed on Nasdaq in May 2026 at an $18 IPO price, raising roughly $279 million in an upsized offering alongside a concurrent private placement, and its 52-week range spans $15.10 to $29.05.
The path to $35 is fundamentally a clinical-development story. As a pre-revenue company, ODTX reported a net loss of roughly $177.6 million over the trailing twelve months and negative EPS (earnings per share), meaning the investment case rests on advancing OD-001 and a broader pipeline — including OD-002 (an SLC15A4 inhibitor) and OD-003 (a TNFR2 agonist) — rather than near-term profitability. Reaching the target would require the stock to trade decisively above its prior $29.05 high and sustain a premium valuation built on trial execution.
What Could Support a Move Toward the Target
- Positive Phase 2a data for OD-001 in ulcerative colitis, with Phase 2b monotherapy and a Phase 2a combination trial expected to begin in the second half of 2026.
- A well-funded balance sheet, with roughly $326 million in cash reported, supporting operations into the development cycle.
- Broadly bullish analyst sentiment, with every firm publishing a target rating the stock Buy/Outperform/Overweight and recent initiations from UBS and Raymond James.
- A differentiated oral mechanism (RIPK2 inhibition) targeting a large inflammatory bowel disease market, plus optionality from additional pipeline programs.
What Could Prevent the Target From Being Reached
- Binary clinical risk: failed or underwhelming later-stage trial data could sharply compress the valuation.
- Cash burn and dilution risk: as a pre-revenue biotech, continued losses may require future equity financing.
- Execution and timeline slippage in initiating or completing Phase 2b and combination studies.
- Valuation sensitivity: the stock already trades above its IPO price but far below analyst targets, and sector-wide risk appetite for early-stage biotech can shift quickly.
Technical Levels and Market Structure
The shares' 52-week range of $15.10 to $29.05 frames the technical picture. The $29 area represents a meaningful prior resistance level, while the $18 IPO price sits near current levels and the $15 zone marks the 52-week low and a key support level. Because the $35 target sits roughly 20% above the 52-week high, reaching it would require a breakout to new highs rather than a move within the existing trading range.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms do not all publish identical time frames. Investors should monitor trial initiation and data-readout timing for OD-001, upcoming quarterly earnings and cash-burn updates, analyst target revisions, and any regulatory or financing developments. No definitive forecast should be assumed from the target itself. From what I see, tracking these milestones closely helps clarify whether the setup remains intact.
Using Tickeron’s AI Daily Buy/Sell Signals
In my own research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get an additional layer of insight on names like ODTX. These signals apply artificial intelligence to scan thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold recommendations driven by technical patterns and market shifts. Pairing this data-driven view with fundamental analysis on clinical progress and analyst targets has helped me stay organized when evaluating pre-revenue biotechs.
Final Assessment
The $35 target is an analyst-derived average — roughly $34.67 across six current, verified price objectives — and it requires a very large move of about 82% from the latest price near $19.23. The case for the move rests on OD-001's clinical promise, a well-capitalized balance sheet, and uniformly bullish sell-side coverage, while the principal obstacles are binary trial risk, continued losses and potential dilution, and the need to break convincingly above the $29 prior high. The wide $27-to-$42 analyst range underscores genuine uncertainty, and no outcome is guaranteed. Investors should watch trial progress and cash position above all else.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ODTX turns negative, indicating new downward trend
ODTX saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator turned negative. In 5 of the 5 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ODTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
ODTX broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for ODTX just turned positive on October 20, 2026. Looking at past instances where ODTX's MACD turned positive, the stock continued to rise in 1 of 2 cases over the following month. The odds of a continued upward trend are 50%.
Following a +1.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where ODTX advanced for three days, in 19 of 23 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. ODTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.194) is normal, around the industry mean (3.498). P/E Ratio (-5.755) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. ODTX's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ODTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement